p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes.

@article{Bidard2008p53SA,
  title={p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes.},
  author={François-Cl{\'e}ment Bidard and M C Matthieu and Philippe Chollet and I Raoefils and Catherine J Abrial and Julien D{\^o}mont and Marc Spielmann and Suzette Delaloge and Fabrice Andr{\'e} and Fr{\'e}d{\'e}rique Penault-Llorca},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2008},
  volume={19 7},
  pages={1261-5}
}
BACKGROUND We hypothesized that, among molecular subclasses of breast cancer, p53 status may have a differential predictive value for the efficacy of anthracyclines/alkylating agents-based regimen. We analysed the efficacy of a preoperative combination between 5-fluorouracil, anthracyclines and cyclophosphamide according to both p53 status and molecular classification. PATIENTS AND METHODS Oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Similar Papers

Loading similar papers…